Evaluate Japan Drug Forecasts: Japan Market Focus No.2
•
0 likes•29 views
Opdivo emerges as market leader in the PD-1/PD-L1 market in Japan - While Opdivo and Keytruda are competing head to head for the global market leadership in the PD-1/PD-L1 space, Opdivo emerges as the dominant player in Japan according to Evaluate Japan Drug Forecasts. For more Japan Market Focus Reports and to find out more about Evaluate Japan Drug Forecasts - http://www.evaluategroup.com/JapanDrugForecasts
Recommended
Recommended
More Related Content
Similar to Evaluate Japan Drug Forecasts: Japan Market Focus No.2
Similar to Evaluate Japan Drug Forecasts: Japan Market Focus No.2 (20)
Recently uploaded
Recently uploaded (20)
Evaluate Japan Drug Forecasts: Japan Market Focus No.2
- 1. Evaluate Japan Drug Forecasts Japan Market Focus No.2 Opdivo emerges as market leader in the PD-1/PD-L1 market in Japan While Opdivo and Keytruda are competing head to head for the global market leadership in the PD-1/PD-L1 space, Opdivo emerges as the dominant player in Japan according to Evaluate Japan Drug Forecasts. The Bristol-Myers Squibb compound, which is marketed in Japan by Ono Pharmaceutical, was launched in 2014 and is set to achieve $1.4 billion by 2022 with a market share of 46% in the segment. The slow down in sales in 2017 is due to a 50% price reduction imposed by the Japan Health Ministry to mitigate budget impact concerns. While sales of Opdivo have been driven primarily by usage in NSCLC patients, by 2022 stomach cancer is set to become Opdivo’s leading indication due to the high incidence of patients for that condition. Despite the late launch, Keytruda is expected to reduce the gap with Opdivo and is forecast to reach a 28% market share by 2022. Imfinzi, Tecentriq and Bavencio are expected to compete for the remaining 25% of the market, consistently with the global outlook for this class. www.evaluate.com Copyright © 2017 Evaluate Ltd. All rights reserved. Source: Evaluate Japan Drug Forecasts. July 2017Top 5 PD-1/PD-L1 Products Studycount 500 1,000 1,500 2,000 2,500 3,000 3,500 0 Imfinzi BavencioKeytrudaOpdivo Tecentriq 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Evaluate Japan Drug Forecasts. July 2017Opdivo – Sales by Indication 2022 Japan Sales 2022 $1.41 bn ¥154.92 bn Indications Japan Sales Japan Sales ($bn) 2022 (¥bn) 2022 Stomach cancer 0.46 50.12 Non-small cell lung cancer (NSCLC) 0.35 38.03 Renal cell carcinoma (RCC) 0.26 28.82 Head & neck cancers 0.12 13.56 Liver cancer 0.10 11.01 Melanoma 0.07 7.84 Oesophageal cancer 0.04 4.77 Hodgkin’s Lymphoma 0.01 0.76 Total $1.41 bn ¥154.92 bn Source: Evaluate Japan Drug Forecasts. July 2017Top 5 PD-1/PD-L1 Products Studycount 500 1,000 1,500 2,000 2,500 3,000 3,500 0 Imfinzi BavencioKeytrudaOpdivo Tecentriq 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Source: Evaluate Japan Drug Forecasts. July 2017Opdivo – Sales by Indication 2022 Japan Sales 2022 $1.41 bn ¥154.92 bn Indications Japan Sales Japan Sales ($bn) 2022 (¥bn) 2022 Stomach cancer 0.46 50.12 Non-small cell lung cancer (NSCLC) 0.35 38.03 Renal cell carcinoma (RCC) 0.26 28.82 Head & neck cancers 0.12 13.56 Liver cancer 0.10 11.01 Melanoma 0.07 7.84 Oesophageal cancer 0.04 4.77 Hodgkin’s Lymphoma 0.01 0.76 Total $1.41 bn ¥154.92 bn View Brochure Find Out More